Safety of probiotics and synbiotics in children under 18 years of age

M. van den Nieuwboer, R. J. Brummer, F. Guarner, L. Morelli, M. Cabana, E. Claassen

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

This study aimed to systematically evaluate safety of probiotics and synbiotics in children ageing 0-18 years. This study is the third and final part in a safety trilogy and an update is provided using the most recent available clinical data (2008-2013) by means of the Common Terminology Clinical Adverse Events (CTCAE version 4.0) classification. Safety aspects are represented and related to number of participants per probiotic strain/culture, study duration, dosage, clinical condition and selected afflictions. Analysis of 74 clinical studies indicated that probiotic and/or synbiotic administration in children is safe with regard to the specific evaluated strains, dosages and duration. The population of children include healthy, immune compromised and obese subjects, as well as subjects with intestinal disorders, infections and inflammatory disorders. This study revealed no major safety concerns, as the adverse events (AEs) were unrelated, or not suspected to be related, to the probiotic or synbiotic product. In general the study products were well tolerated. Overall, AEs occurred more frequent in the control arm compared to children receiving probiotics and/or synbiotics. Furthermore, the results indicate inadequate reporting and classification of AEs in the majority of the studies. In addition, generalizability of conclusions are greatly limited by the inconsistent, imprecise and potentially incomplete reporting as well as the variation in probiotic strains, dosages, administration regimes, study populations and reported outcomes.

Original languageEnglish (US)
Pages (from-to)615-630
Number of pages16
JournalBeneficial Microbes
Volume6
Issue number5
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Synbiotics
Probiotics
Safety
Terminology
Population
Infection

Keywords

  • Children
  • Prebiotics
  • Probiotics
  • Safety
  • Synbiotics

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)

Cite this

van den Nieuwboer, M., Brummer, R. J., Guarner, F., Morelli, L., Cabana, M., & Claassen, E. (2015). Safety of probiotics and synbiotics in children under 18 years of age. Beneficial Microbes, 6(5), 615-630. https://doi.org/10.3920/BM2014.0157

Safety of probiotics and synbiotics in children under 18 years of age. / van den Nieuwboer, M.; Brummer, R. J.; Guarner, F.; Morelli, L.; Cabana, M.; Claassen, E.

In: Beneficial Microbes, Vol. 6, No. 5, 01.01.2015, p. 615-630.

Research output: Contribution to journalArticle

van den Nieuwboer, M, Brummer, RJ, Guarner, F, Morelli, L, Cabana, M & Claassen, E 2015, 'Safety of probiotics and synbiotics in children under 18 years of age', Beneficial Microbes, vol. 6, no. 5, pp. 615-630. https://doi.org/10.3920/BM2014.0157
van den Nieuwboer M, Brummer RJ, Guarner F, Morelli L, Cabana M, Claassen E. Safety of probiotics and synbiotics in children under 18 years of age. Beneficial Microbes. 2015 Jan 1;6(5):615-630. https://doi.org/10.3920/BM2014.0157
van den Nieuwboer, M. ; Brummer, R. J. ; Guarner, F. ; Morelli, L. ; Cabana, M. ; Claassen, E. / Safety of probiotics and synbiotics in children under 18 years of age. In: Beneficial Microbes. 2015 ; Vol. 6, No. 5. pp. 615-630.
@article{3f6f1ab023e74b93822c026bb96f9460,
title = "Safety of probiotics and synbiotics in children under 18 years of age",
abstract = "This study aimed to systematically evaluate safety of probiotics and synbiotics in children ageing 0-18 years. This study is the third and final part in a safety trilogy and an update is provided using the most recent available clinical data (2008-2013) by means of the Common Terminology Clinical Adverse Events (CTCAE version 4.0) classification. Safety aspects are represented and related to number of participants per probiotic strain/culture, study duration, dosage, clinical condition and selected afflictions. Analysis of 74 clinical studies indicated that probiotic and/or synbiotic administration in children is safe with regard to the specific evaluated strains, dosages and duration. The population of children include healthy, immune compromised and obese subjects, as well as subjects with intestinal disorders, infections and inflammatory disorders. This study revealed no major safety concerns, as the adverse events (AEs) were unrelated, or not suspected to be related, to the probiotic or synbiotic product. In general the study products were well tolerated. Overall, AEs occurred more frequent in the control arm compared to children receiving probiotics and/or synbiotics. Furthermore, the results indicate inadequate reporting and classification of AEs in the majority of the studies. In addition, generalizability of conclusions are greatly limited by the inconsistent, imprecise and potentially incomplete reporting as well as the variation in probiotic strains, dosages, administration regimes, study populations and reported outcomes.",
keywords = "Children, Prebiotics, Probiotics, Safety, Synbiotics",
author = "{van den Nieuwboer}, M. and Brummer, {R. J.} and F. Guarner and L. Morelli and M. Cabana and E. Claassen",
year = "2015",
month = "1",
day = "1",
doi = "10.3920/BM2014.0157",
language = "English (US)",
volume = "6",
pages = "615--630",
journal = "Beneficial microbes",
issn = "1876-2883",
publisher = "Wageningen Academic Publishers",
number = "5",

}

TY - JOUR

T1 - Safety of probiotics and synbiotics in children under 18 years of age

AU - van den Nieuwboer, M.

AU - Brummer, R. J.

AU - Guarner, F.

AU - Morelli, L.

AU - Cabana, M.

AU - Claassen, E.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - This study aimed to systematically evaluate safety of probiotics and synbiotics in children ageing 0-18 years. This study is the third and final part in a safety trilogy and an update is provided using the most recent available clinical data (2008-2013) by means of the Common Terminology Clinical Adverse Events (CTCAE version 4.0) classification. Safety aspects are represented and related to number of participants per probiotic strain/culture, study duration, dosage, clinical condition and selected afflictions. Analysis of 74 clinical studies indicated that probiotic and/or synbiotic administration in children is safe with regard to the specific evaluated strains, dosages and duration. The population of children include healthy, immune compromised and obese subjects, as well as subjects with intestinal disorders, infections and inflammatory disorders. This study revealed no major safety concerns, as the adverse events (AEs) were unrelated, or not suspected to be related, to the probiotic or synbiotic product. In general the study products were well tolerated. Overall, AEs occurred more frequent in the control arm compared to children receiving probiotics and/or synbiotics. Furthermore, the results indicate inadequate reporting and classification of AEs in the majority of the studies. In addition, generalizability of conclusions are greatly limited by the inconsistent, imprecise and potentially incomplete reporting as well as the variation in probiotic strains, dosages, administration regimes, study populations and reported outcomes.

AB - This study aimed to systematically evaluate safety of probiotics and synbiotics in children ageing 0-18 years. This study is the third and final part in a safety trilogy and an update is provided using the most recent available clinical data (2008-2013) by means of the Common Terminology Clinical Adverse Events (CTCAE version 4.0) classification. Safety aspects are represented and related to number of participants per probiotic strain/culture, study duration, dosage, clinical condition and selected afflictions. Analysis of 74 clinical studies indicated that probiotic and/or synbiotic administration in children is safe with regard to the specific evaluated strains, dosages and duration. The population of children include healthy, immune compromised and obese subjects, as well as subjects with intestinal disorders, infections and inflammatory disorders. This study revealed no major safety concerns, as the adverse events (AEs) were unrelated, or not suspected to be related, to the probiotic or synbiotic product. In general the study products were well tolerated. Overall, AEs occurred more frequent in the control arm compared to children receiving probiotics and/or synbiotics. Furthermore, the results indicate inadequate reporting and classification of AEs in the majority of the studies. In addition, generalizability of conclusions are greatly limited by the inconsistent, imprecise and potentially incomplete reporting as well as the variation in probiotic strains, dosages, administration regimes, study populations and reported outcomes.

KW - Children

KW - Prebiotics

KW - Probiotics

KW - Safety

KW - Synbiotics

UR - http://www.scopus.com/inward/record.url?scp=84944404934&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944404934&partnerID=8YFLogxK

U2 - 10.3920/BM2014.0157

DO - 10.3920/BM2014.0157

M3 - Article

C2 - 25809217

AN - SCOPUS:84944404934

VL - 6

SP - 615

EP - 630

JO - Beneficial microbes

JF - Beneficial microbes

SN - 1876-2883

IS - 5

ER -